Почетна › Рак на бели дробови со не-мали клетки › Кентаки › Lexington
Клинички испитувања за Рак на бели дробови со не-мали клетки во Lexington, KY
23 студии за Рак на бели дробови со не-мали клетки бараат учесници на локации во и околу Lexington (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.
Официјален текст на студијата (англиски)
Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Се регрутираФаза 3
- Baptist Health Lexington, Lexington
- Baptist Health Hamburg, Lexington
- University of Kentucky/Markey Cancer Center, Lexington
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Се регрутираФаза 2
- Local Institution - 0034, Lexington
- Local Institution - 0171, Lexington
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Се регрутираФаза 2
- University of Kentucky Chandler Medical Center ( Site 0019), Lexington
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Се регрутираФаза 3
- University of Kentucky Chandler Medical Center, Lexington
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Се регрутираФаза 3
- Research Site, Lexington
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Се регрутираФаза 3
- Baptist Health Lexington, Lexington
- Baptist Health Hamburg, Lexington
Pan-tumor MRD Study
Се регрутираНабљудувачка студија
- Baptist Health Lexington, Lexington
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Се регрутираФаза 3
- Baptist Health Lexington, Lexington
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Се регрутираФаза 2/3
- Baptist Health Lexington, Lexington
- University of Kentucky Chandler Medical Center (UKCMC) - Markey Cancer Center (Lucille P. Markey Cancer Center), Lexington
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Се регрутираФаза 3
- Research Site, Lexington
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Се регрутираФаза 3
- Clinical Study Site, Lexington
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Се регрутираФаза 2/3
- Lexington Medical Cancer Center Hematology/Oncology, Lexington
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Се регрутираФаза 1/2
- Markey Cancer Center, Lexington
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Се регрутираФаза 2/3
- Baptist Health Lexington /ID# 261823, Lexington
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Се регрутираФаза 3
- CHI Saint Joseph Cancer Center - East, Lexington
- University of Kentucky Chandler Medical Center, Lexington
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Се регрутираФаза 2
- University of Kentucky ( Site 0019), Lexington
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Се регрутираФаза 1
- University of Kentucky Chandler Medical Center, Lexington
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Се регрутираФаза 1
- UK Markey Cancer Center, Lexington
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Се регрутираФаза 2
- University of Kentucky/Markey Cancer Center, Lexington
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Се регрутираФаза 2
- University of Kentucky/Markey Cancer Center, Lexington
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Се регрутираФаза 2/3
- University of Kentucky/Markey Cancer Center, Lexington
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Се регрутираФаза 2
- University of Kentucky/Markey Cancer Center, Lexington
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Се регрутираНабљудувачка студија
- Saint Joseph Hospital East, Lexington
Испитувања за Рак на бели дробови со не-мали клетки во други градови
- Houston, TX145 студии
- New York City, NY121 студија
- Arlington, VA104 студии
- Nashville, TN97 студии
- Boston, MA90 студии
- Los Angeles, CA87 студии
- St. Louis, MO73 студии
- Chicago, IL61 студија
- Baltimore, MD60 студии
- San Antonio, TX59 студии
- Columbus, OH57 студии
- Washington, DC55 студии
Други студии во Lexington
- Рак на бели дробови18 студии
- Карцином на јајниците16 студии
- Рак на простата14 студии
- Рак (сите типови)14 студии
- Рак на дојка14 студии
- Метастатски карцином11 студии
- Колоректален карцином11 студии
- Срцева слабост11 студии
- Меланом10 студии
- Акутна миелоидна леукемија10 студии
- Дебелина10 студии
- Сквамозноклеточен карцином на глава и врат9 студии
Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.